Robert L. Hitchcock, Managing Partner

Phone: 650-327-9710 / 650-868-0288
Email: bob@trgba.com

Bob began his career in sales with IBM in San Francisco followed by increasingly responsible sales management positions in Toronto and Los Angeles. From IBM Bob was recruited to lead sales and marketing operations for the Computer Products Division of Ampex Corporation (A Fortune 500 company). Under Bob’s leadership, the division grew from $60 million to $122 million in sales over a two-year period.

In the 1980’s Bob led the sales and marketing operation of Navteq, the world leader in computer navigation systems and also directed international sales and marketing operations for The Complete PC, an industry leading computer peripherals company. Bob established and built their OEM operation and expanded their international operation into 10 new major European and Asian markets.

In the 90’s Bob was President and CEO of Datavision Technologies, a one-to-one direct marketing company that developed and patented the process of delivering customized video and audio presentations for interactive television and the Internet. Under Bob’s guidance the company created and launched a professional services product for the education market that became an industry standard and was named product of the year. Additionally the company developed personalized direct marketing programs for multiple major corporations such as Lexus, American Express, and The Disney Company. In 1999 it was successfully sold to an east coast firm.

Bob is the Managing Partner of The Results Group and is directly involved and the key point person in every client relationship.

Bob’s clients have included both privately funded companies and publicly traded corporations. The firm works on a nationwide basis with particular emphasis on the western United States.

Bob has a BS in marketing from the University of Oregon and an MBA with distinction in international management from the Thunderbird Graduate School of Global Management. 

After undergraduate school and prior to receiving his MBA Bob was an officer and flew for the U.S. Navy.

 

 

 

Wendy R. Hitchcock, Advisory Consulting Partner

Phone: 650-327-9710 / 650-858-0287
Email: wendy.hitchcock@gmail.com

Wendy Hitchcock has successfully led critical growth transitions for life science technology and information companies, focusing on building sustainable value through strategic alliance, financing and market initiatives.

Ms. Hitchcock is the Chief Executive Officer and a member of the Board of Trustees of Vascular Cures (vascularcures.org), a non-profit medical organization dedicated to accelerating research into the cause, prevention and treatment of vascular disease.  

In addition to providing advisory consulting services to The Results Group, Ms. Hitchcock is also a member of the Board of Directors of Mercator Medsystems (mercatormed.com) and was the Chief Business Officer and Executive Vice President of the firm.  Mercator Medsystems is a medical device company that has developed a catheter based micro syringe that enables site specific drug delivery anywhere in the body.

Prior to Mercator Ms. Hitchcock was CEO of LabVelocity, which was sold to Infotrieve Inc., a global information provider to scientific and technology customers. LabVelocity provides structured content and search technology to improve R&D decision-making for bio-pharma and its scientists, maximize yield on research spending and increase sales for manufacturers of research products.

Prior to LabVelocity, Ms. Hitchcock was interim SVP of Operations for Affymax following an investor buyout from GlaxoSmithKline in 2001. She managed all the business, organizational and legal aspects of its transition from a pharmaceutical research unit of GSK into a privately held independent company. Affymax successfully completed its IPO in December, 2006.

She joined ACLARA BioSciences, a life science tools/technology company in 1999 as Chief Financial Officer, and led its IPO in 2000. Prior to this Ms. Hitchcock completed a strategic acquisition as VP corporate development for a public ophthalmic device company, and was Chief Financial Officer for SyStemix, a stem cell and gene therapy company, from 1993 through its acquisition by Novartis in 1997.

Prior to 1993 Wendy was CEO of a private investment company and Practice Leader launching a new venture within a public consulting and accounting firm. She has a B.A. with honors (Phi Beta Kappa) from Brown University and an MBA, Finance with honors from the University of California at Los Angeles.